March 18, 2013
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that
Anna Malm Bernsten
and Boel Flodgren have been elected to the Company's Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive.
Anna Malm Bernsten
has more than 25 years of international marketing and sales experience in the healthcare industry. She was until recently Chief Marketing Officer at GE Healthcare Life Sciences, where she established a marketing leadership team, developing branding and communication strategies for the company's key brands. Anna also gained global sales experience as Vice President Global Sales at Aerocrine AB and developed her leadership skills as Chief Executive Officer at Carmeda AB. Anna is currently on the board of a number of companies including Nolato AB, CellaVision AB, Medivir AB and Fagerhult AB and she was previously on the board of Biophausia AB. Anna has an MSc in Chemical Engineering from the Royal Institute of Technology,
Boel Flodgren is a Senior Professor of Business Law at the School of Economics and Management at
University. She brings to NeuroVive a wealth of academic knowledge in law and regulatory issues. She was the President of
University for ten years and has been awarded honorary doctorate degrees from HANKEN (The Swedish School of Economics and Business Administration),
and from the
University of Oslo
, Norway. Her research focuses on Contract Law and International Trade Law. Boel has served on the Boards of the Universities of
and is currently a Director of AB Industrivärden.
Anna and Boel join
, who was appointed in 2012, on NeuroVive's seven person Board. Helena has over 30 years of experience in equity fund and asset management. Helena is managing partner and co-founder of Nordic Investor Services AB, where she is responsible for strategic development and marketing. Prior to this position, she was Chief Executive Officer at Neonet Securities AB, where she developed an international stock exchange trading network and prepared the Company for its listing on the Stockholm Stock Exchange in 2000. She holds a BSc in Business and Economics from
Stockholm School of Economics
and completed the "International Banking Programme" at INSEAD. Helena is a Director of several companies, including SBAB Bank, Uniflex Bemanning, Stampen and Collector.
Greg Batcheller, Chairman of NeuroVive Pharmaceutical said:
"NeuroVive's ability to attract such high calibre board members as Anna and Boel highlights our attractive growth potential as one of the world's leading companies in mitochondrial medicine. I am pleased that NeuroVive is clearly in the vanguard of promoting gender equality at Board level. With these new appointments, alongside the appointment of Helena last year, women now account for 3 out of the 7 person Board of Directors. I believe that with these appointments we now have a balanced Board which has the experience, leadership and independence to support NeuroVive through its next stage of growth as we advance our attractive pipeline of novel mitochondrial medicines and as we prepare for listing on the Nasdaq OMX Stockholm Stock Exchange."
About NeuroVive Pharmaceutical AB (publ)